#METABOLOMICS WORKBENCH hormel101_20180414_091953_mwtab.txt DATATRACK_ID:1377 STUDY_ID:ST000961 ANALYSIS_ID:AN001575 PROJECT_ID:PR000659 VERSION 1 CREATED_ON April 19, 2018, 10:44 pm #PROJECT PR:PROJECT_TITLE Mayo Pilot and Feasibility: The Influence of Sugar, Artificial Sweeteners, and PR:PROJECT_TITLE the Microbiome on Metabolism PR:PROJECT_SUMMARY As diabetes becomes a growing heath concern, afflicting nearly 25.8 million PR:PROJECT_SUMMARY people in the United States and nearly 220 million people worldwide, there has PR:PROJECT_SUMMARY been an increased awareness of environmental factors like diet that are PR:PROJECT_SUMMARY contributing to the disease. In diabetic patients, a major causal factor PR:PROJECT_SUMMARY contributing to progression of the disease is hyperglycemia, although the PR:PROJECT_SUMMARY underlying mechanisms by which hyperglycemia impairs homeostatic processes are PR:PROJECT_SUMMARY not well understood. While we know that early intensive glycemic control reduces PR:PROJECT_SUMMARY the risk of cardiovascular complications in humans and rodent models, there is a PR:PROJECT_SUMMARY large gap in studies of the etiology of hyperglycemia-induced alterations in the PR:PROJECT_SUMMARY disease. To combat high sugar diets that could contribute to diabetes and PR:PROJECT_SUMMARY subsequent hyperglycemia, non-caloric artificial sweeteners have become one of PR:PROJECT_SUMMARY the most utilized food additives worldwide due to their consideration as a low PR:PROJECT_SUMMARY caloric substitute. However, supporting scientific data as to the safety of PR:PROJECT_SUMMARY these non-caloric artificial sweeteners is limited and controversial. The PR:PROJECT_SUMMARY negative implications of consuming a high sugar diet on overall health have long PR:PROJECT_SUMMARY been linked to diabetes, obesity, and resulting systemic health problems; PR:PROJECT_SUMMARY however, it was not until recently that the negative impact of consuming PR:PROJECT_SUMMARY artificial sweeteners in the place of sugar had been increasingly recognized. PR:PROJECT_SUMMARY Recent evidence also suggests that a diet rich in artificial sweeteners can PR:PROJECT_SUMMARY induce glucose intolerance through the alteration of the gut microbiome. We PR:PROJECT_SUMMARY hypothesize that a specific subset of plasma metabolites are generated as a PR:PROJECT_SUMMARY result from a diet rich in commonly used artificial sweeteners and their PR:PROJECT_SUMMARY subsequent processing by the gut microbiome, which could ultimately lead to PR:PROJECT_SUMMARY impaired glycemic control and negative physiological health outcomes. To test PR:PROJECT_SUMMARY this hypothesis this study will 1) administer a diet high in glucose, fructose, PR:PROJECT_SUMMARY and 4 common artificial sweeteners separately to rats followed by a plasma PR:PROJECT_SUMMARY metabolic analysis (AIM 1) and 2) treat the gut microbiota with antibiotics in PR:PROJECT_SUMMARY these animals to observe how alterations of the microbiome influence the plasma PR:PROJECT_SUMMARY metabolic profile in animals receiving the altered diets (AIM 2). The resulting PR:PROJECT_SUMMARY data will give us insights into the influence of high sugar and artificial PR:PROJECT_SUMMARY sweetener diets on homeostatic metabolic processes and dive into the symbiotic PR:PROJECT_SUMMARY relationship of the gut microbiome with this process. This data will provide PR:PROJECT_SUMMARY crucial insights into the dietary use of artificial sweeteners in the PR:PROJECT_SUMMARY replacement of sugars and how it alters metabolic pathways that could PR:PROJECT_SUMMARY potentially lead to altered states of obesity, diabetes, and cardiovascular PR:PROJECT_SUMMARY disease. PR:INSTITUTE Mayo Clinic PR:LAST_NAME Hoffmann PR:FIRST_NAME Brian PR:ADDRESS 8701 Watertown Plank Road Milwaukee, WI 53226 PR:EMAIL bhoffmann@mcw.edu PR:PHONE 414-955-8671 #STUDY ST:STUDY_TITLE The Influence of Sugar, Artificial Sweeteners, and the Microbiome on Rodent ST:STUDY_TITLE Amino Acids (part IV) ST:STUDY_SUMMARY Targeted Amino Acid panel of rodents treated with diets rich in commonly used ST:STUDY_SUMMARY artifically sweeteners will be assessed in this study. We hypothesized that a ST:STUDY_SUMMARY specific subset of plasma metabolites are generated as a result from a diet rich ST:STUDY_SUMMARY in commonly used artificial sweeteners and their subsequent processing by the ST:STUDY_SUMMARY gut microbiome, which could ultimately lead to impaired glycemic control and ST:STUDY_SUMMARY negative physiological health outcomes. To test this hypothesis we administered ST:STUDY_SUMMARY normal, high glucose, fructose, aspartame, and acesulfame potassium diets to ST:STUDY_SUMMARY rats for 3 weeks, followed by a plasma collection through cardiac puncture and ST:STUDY_SUMMARY metabolic analysis. We also treated the gut microbiota with in rats with the ST:STUDY_SUMMARY same diets plus bacitracin/streptomycin to observe how alterations of the ST:STUDY_SUMMARY microbiome influence the plasma metabolic profile in these animals. The ST:STUDY_SUMMARY resulting data will give us insights into the influence of high sugar and ST:STUDY_SUMMARY artificial sweetener diets on homeostatic metabolic processes and dive into the ST:STUDY_SUMMARY symbiotic relationship of the gut microbiome with this process. ST:INSTITUTE Mayo Clinic ST:LAST_NAME Hoffmann ST:FIRST_NAME Brian ST:ADDRESS 8701 Watertown Plank Road Milwaukee, WI 53226 ST:EMAIL bhoffmann@mcw.edu ST:PHONE 414-955-8671 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - ms6707-6 Group:Group 1 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-39 Group:Group 1 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-12 Group:Group 1 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-31 Group:Group 1 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-38 Group:Group 1 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-7 Group:Group 1 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-50 Group:Group 10 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-59 Group:Group 10 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-51 Group:Group 10 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-53 Group:Group 10 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-54 Group:Group 10 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-57 Group:Group 10 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-60 Group:Group 10 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-20 Group:Group 2 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-21 Group:Group 2 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-32 Group:Group 2 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-42 Group:Group 2 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-10 Group:Group 2 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-30 Group:Group 2 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-3 Group:Group 3 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-4 Group:Group 3 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-5 Group:Group 3 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-27 Group:Group 3 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-19 Group:Group 3 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-28 Group:Group 3 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-14 Group:Group 4 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-33 Group:Group 4 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-9 Group:Group 4 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-29 Group:Group 4 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-34 Group:Group 4 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-47 Group:Group 4 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-15 Group:Group 5 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-17 Group:Group 5 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-16 Group:Group 5 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-23 Group:Group 5 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-26 Group:Group 5 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-43 Group:Group 5 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-25 Group:Group 6 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-41 Group:Group 6 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-44 Group:Group 6 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-2 Group:Group 6 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-13 Group:Group 6 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-18 Group:Group 6 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-11 Group:Group 7 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-46 Group:Group 7 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-48 Group:Group 7 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-1 Group:Group 7 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-22 Group:Group 7 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-35 Group:Group 7 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-8 Group:Group 8 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-36 Group:Group 8 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-40 Group:Group 8 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-45 Group:Group 8 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-24 Group:Group 8 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-37 Group:Group 8 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-49 Group:Group 9 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-52 Group:Group 9 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-55 Group:Group 9 Gender=F; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-58 Group:Group 9 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 SUBJECT_SAMPLE_FACTORS - ms6707-56 Group:Group 9 Gender=M; Sample=Plasma; Species=Rat; study=ms6707 #COLLECTION CO:COLLECTION_SUMMARY "Samples were collected by cardiac puncture and plasma was collected following CO:COLLECTION_SUMMARY standard centrifugation steps. Immediately following the samples were separated CO:COLLECTION_SUMMARY into 500 uL aliquots in 600 uL tubes and frozen in liquid nitrogen. CO:SAMPLE_TYPE Blood (plasma) #TREATMENT TR:TREATMENT_SUMMARY "We administered normal, high glucose, aspartame, and acesulfame potassium diets TR:TREATMENT_SUMMARY to rats for 3 weeks, followed by a plasma collection through cardiac puncture TR:TREATMENT_SUMMARY and metabolic analysis (Group 1-4 samples). We also treated the gut microbiota TR:TREATMENT_SUMMARY with in rats with the same diets plus bacitracin/streptomycin to observe how TR:TREATMENT_SUMMARY alterations of the microbiome influence the plasma metabolic profile in these TR:TREATMENT_SUMMARY animals (Groups 5-8). The samples here contain the fructose diet group (Group TR:TREATMENT_SUMMARY 9). We also treated the gut microbiota with in rats with the same diets plus TR:TREATMENT_SUMMARY bacitracin/streptomycin to observe how alterations of the microbiome influence TR:TREATMENT_SUMMARY the plasma metabolic profile in these animals (Groups 5-8). The samples here TR:TREATMENT_SUMMARY contain the fructose diet group with antibiotic (Group 10). For the gut TR:TREATMENT_SUMMARY microbiota experiment, during the last 10 days of the diet subsets of all groups TR:TREATMENT_SUMMARY will have bacitracin and streptomycin (B/S) provided in their drinking water TR:TREATMENT_SUMMARY (0.5g/250 mL). The resulting data will give us insights into the influence of TR:TREATMENT_SUMMARY high sugar and artificial sweetener diets on homeostatic metabolic processes and TR:TREATMENT_SUMMARY dive into the symbiotic relationship of the gut microbiome with this process. TR:TREATMENT_SUMMARY Group1 = normal diet Group2 = high glucose diet Group3 = aspartame diet Group4 = TR:TREATMENT_SUMMARY acesulfame potassium diet Group5 = rat gut microbiota normal diet + antibotics TR:TREATMENT_SUMMARY Group6 = rat gut microbiota high glucose diet + antibotics Group7 = rat gut TR:TREATMENT_SUMMARY microbiota aspartame diet + antibotics Group8 = rat gut acesulfame potassium TR:TREATMENT_SUMMARY diet + antibotics Group9 = fructose diet Group10 = rat gut fructose diet + TR:TREATMENT_SUMMARY antibotics" #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Concentration of AA + metabolites in rat plasma #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Waters Acquity CH:COLUMN_NAME Waters Acquity BEH C18 (150 x 2.1mm, 1.7um) #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME Thermo Quantum Ultra MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE POSITIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS uM MS_METABOLITE_DATA_START Samples ms6707-1 ms6707-2 ms6707-3 ms6707-4 ms6707-5 ms6707-6 ms6707-7 ms6707-8 ms6707-9 ms6707-10 ms6707-11 ms6707-12 ms6707-13 ms6707-14 ms6707-15 ms6707-16 ms6707-17 ms6707-18 ms6707-19 ms6707-20 ms6707-21 ms6707-22 ms6707-23 ms6707-24 ms6707-25 ms6707-26 ms6707-27 ms6707-28 ms6707-29 ms6707-30 ms6707-31 ms6707-32 ms6707-33 ms6707-34 ms6707-35 ms6707-36 ms6707-37 ms6707-38 ms6707-39 ms6707-40 ms6707-41 ms6707-42 ms6707-43 ms6707-44 ms6707-45 ms6707-46 ms6707-47 ms6707-48 ms6707-49 ms6707-50 ms6707-51 ms6707-52 ms6707-53 ms6707-54 ms6707-55 ms6707-56 ms6707-57 ms6707-58 ms6707-59 ms6707-60 Factors Group:Group 7 Group:Group 6 Group:Group 3 Group:Group 3 Group:Group 3 Group:Group 1 Group:Group 1 Group:Group 8 Group:Group 4 Group:Group 2 Group:Group 7 Group:Group 1 Group:Group 6 Group:Group 4 Group:Group 5 Group:Group 5 Group:Group 5 Group:Group 6 Group:Group 3 Group:Group 2 Group:Group 2 Group:Group 7 Group:Group 5 Group:Group 8 Group:Group 6 Group:Group 5 Group:Group 3 Group:Group 3 Group:Group 4 Group:Group 2 Group:Group 1 Group:Group 2 Group:Group 4 Group:Group 4 Group:Group 7 Group:Group 8 Group:Group 8 Group:Group 1 Group:Group 1 Group:Group 8 Group:Group 6 Group:Group 2 Group:Group 5 Group:Group 6 Group:Group 8 Group:Group 7 Group:Group 4 Group:Group 7 Group:Group 9 Group:Group 10 Group:Group 10 Group:Group 9 Group:Group 10 Group:Group 10 Group:Group 9 Group:Group 9 Group:Group 10 Group:Group 9 Group:Group 10 Group:Group 10 Histidine 63.1 96.2 77.8 62.5 79.7 52.1 101.0 96.1 86.9 102.1 98.1 83.4 79.9 93.0 119.6 99.4 68.3 67.8 123.8 111.3 79.6 79.4 109.5 86.1 96.8 91.6 89.5 89.1 67.4 89.7 87.1 89.3 133.9 83.0 85.4 118.1 102.7 81.3 97.9 115.2 76.6 90.2 105.6 131.4 113.2 95.5 76.4 70.6 121.3 72.1 91.0 69.8 76.2 73.0 72.1 83.8 84.5 74.6 50.5 60.9 Hydroxyproline 51.0 64.6 62.3 48.3 63.8 65.7 58.9 79.8 70.6 61.0 65.0 47.2 55.9 73.0 57.3 58.5 26.0 49.2 68.7 51.9 62.5 69.9 61.4 58.6 49.9 53.9 59.7 65.4 51.0 57.3 55.7 51.9 58.1 56.7 53.1 58.2 41.8 44.9 51.1 70.4 59.2 46.6 69.2 52.0 64.1 60.1 44.6 38.5 54.5 48.2 57.0 64.7 60.0 60.4 48.2 54.3 57.1 56.0 57.8 39.4 1-Methylhistidine 1.2 3.0 2.2 0.7 2.3 2.1 1.8 1.2 2.5 2.5 1.7 3.2 1.4 1.2 2.3 1.7 1.7 2.4 1.6 2.7 2.5 2.6 2.0 1.9 2.0 2.2 2.7 3.7 1.3 2.0 2.2 1.6 2.1 2.5 1.6 1.4 1.8 1.1 1.9 1.4 3.8 1.2 1.4 2.6 1.0 1.0 1.3 0.9 1.7 2.5 1.9 1.8 1.8 2.6 3.6 2.1 1.8 2.4 1.4 1.7 3-Methylhistidine 1.3 4.0 3.0 3.5 4.5 1.2 2.9 4.3 2.4 3.1 3.9 3.0 2.0 5.1 3.5 3.3 5.5 2.2 4.1 3.6 3.0 1.7 3.7 2.9 2.8 2.9 2.2 2.8 3.3 3.4 3.0 2.2 2.3 3.4 1.8 2.4 1.7 1.5 3.3 3.3 3.6 2.0 2.4 2.6 1.3 2.1 2.2 1.5 2.4 2.0 2.3 2.5 1.7 3.6 1.8 2.9 2.8 2.0 1.8 2.1 Asparagine 107.5 131.5 96.0 71.8 97.8 113.8 135.6 140.6 124.5 110.2 128.0 107.9 120.3 97.9 70.7 108.5 76.4 133.9 161.0 128.6 109.1 96.9 144.4 159.9 127.3 108.5 121.6 123.3 83.5 103.7 128.5 110.8 123.8 116.0 127.2 139.4 117.5 105.6 110.9 160.1 135.2 76.2 157.9 112.9 99.7 115.3 96.9 97.7 107.9 66.2 90.7 97.9 95.3 109.7 86.7 78.7 113.9 106.6 68.5 70.4 Phosphoethanolamine 5.4 3.9 4.0 5.1 5.7 4.8 6.2 5.2 4.0 5.1 5.3 4.2 4.8 5.3 6.2 2.7 5.2 3.6 4.9 5.7 5.5 5.5 4.6 6.3 7.8 3.8 5.1 5.5 5.0 5.0 6.8 7.7 11.8 6.1 8.3 7.1 7.6 7.0 10.2 8.3 8.3 9.2 10.9 9.8 7.6 8.1 8.0 8.8 6.7 7.2 4.6 8.6 7.4 6.6 6.8 8.7 6.8 6.1 6.0 7.3 Arginine 219.0 288.0 216.2 161.3 234.5 200.7 204.9 281.4 280.2 245.8 283.4 210.9 265.6 230.3 199.8 273.7 158.6 289.5 280.8 232.6 241.8 201.6 270.3 276.0 245.6 226.9 230.9 235.6 205.0 191.0 221.7 193.7 257.9 263.8 249.9 240.4 206.6 209.7 231.2 315.3 266.3 150.8 294.6 229.8 217.9 276.1 215.5 218.2 191.4 170.3 172.7 133.8 161.8 202.6 147.1 124.0 198.6 166.8 143.6 144.0 Carnosine 1.6 1.7 1.7 1.8 1.3 0.9 1.3 1.0 1.7 1.6 0.8 1.3 1.9 1.5 1.4 1.9 1.3 2.4 2.2 1.7 2.1 1.0 1.3 1.4 1.3 2.1 2.1 2.2 1.0 2.2 1.2 2.7 1.8 1.0 1.6 1.1 1.2 1.9 2.2 0.8 1.3 2.1 2.9 1.0 0.8 1.8 1.7 1.1 2.0 0.8 1.2 1.8 1.5 1.1 1.8 1.9 1.4 2.5 1.0 1.3 Taurine 174.7 154.9 143.4 166.1 122.4 106.7 97.9 172.3 112.7 103.3 145.3 92.1 122.5 180.7 261.3 139.4 277.4 125.2 157.9 205.0 148.1 152.4 170.1 201.1 216.9 119.0 124.8 127.2 155.6 123.1 92.4 102.6 164.5 109.4 154.1 173.2 139.0 98.0 73.5 154.8 167.3 127.5 180.4 224.4 149.3 160.6 102.4 136.5 58.9 77.0 83.6 85.3 108.5 123.1 84.4 82.0 152.0 67.8 81.4 104.4 Anserine 1.0 0.7 0.8 0.9 0.7 0.5 0.5 0.4 0.8 0.8 0.4 0.6 0.9 0.8 0.8 0.9 1.0 0.9 0.9 1.3 1.1 0.6 0.5 0.4 0.9 1.0 1.1 0.8 0.5 0.9 0.5 1.0 0.9 0.5 0.8 0.5 0.6 0.9 0.9 0.4 0.8 1.1 1.0 0.6 0.5 1.0 0.8 0.6 1.0 0.4 0.9 0.7 0.8 0.7 0.9 0.8 0.7 1.2 0.5 0.6 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name Histidine Hydroxyproline 1-Methylhistidine 3-Methylhistidine Asparagine Phosphoethanolamine Arginine Carnosine Taurine Anserine METABOLITES_END #END